2026 Asia BioTech Expo - Speed to patients, industry chain integration

研报英文原文证据摘录

2026 Asia BioTech Expo - Speed to patients, industry chain integration

ion

This year’s Innovation Forum highlights emerging therapies, gene editing and non-clinicalJoseph Wang

(886-2) 2781-5995 ext 37033 models, and AI-driven drug development as key topics, extending to advanced therapies

tsuliang.wang@fubon.com such as ADCs, radiopharmaceuticals, and cell and gene therapies. AI applications have

evolved from early-stage drug design and candidate screening to subject recruitment,

clinical trial initiation, data analysis, and global clinical management, which is expected to

enhance drug discovery and clinical development efficiency. Domestic new drug exhibitors

are also pursuing diversified commercialization paths, including new formulations, late-

stage clinical trials, overseas licensing, emerging therapies, and expanding indications for

existing products. As therapy and process complexity increases, CDMO services have

evolved from traditional capacity outsourcing to process development, analytical methods,

technology transfer, clinical supply, and commercial-scale production. The industry’s

competitive focus has shifted from single capacity scale to technology platforms, the ability

to scale up clinical projects to commercial production, and cross-regional manufacturing

and supply chain deployment. In addition, this exhibition strengthens new drug licensing,

co-development, cross-border clinical trials, and global resource matching through

national pavilions, regional cooperation forums, and BIO Partnering. We recommend

focusing on late-stage new drug pipelines and commercialization progress, global CDMO

manufacturing deployment, and the overseas licensing and cross-border collaboration

achievements of domestic biotech companies.

See last page for disclaimer 1